A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2012 Planned number of patients changed from 300 to 369 as reported by European Clinical Trials Database record.
- 13 Jan 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.